Search
Displaying results 641 to 650 of 673.
Anti-infectives from Microbiota
The department of Prof Christine Beemelmanns focuses on the identification and functional analysis of novel anti-infective natural products from microbial communities. Co-cultivation studies as well as cell-based assays in combination with chemical-analytical and molecular-biological methods are used to evaluate and prioritize novel natural product producers. The department uses established and innovative metabolomic-, activity and genome-based methods to identify and determine the structure of the secreted natural products. Based on the isolated novel natural substances, the functional analysis and evaluation of their range of effects is carried out. This department is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .
Chemical Biology
In their ongoing quest for new therapies against pathogens, scientists are focusing primarily on chemical agents. Discovering new bioactive compounds, characterising their functionality and optimising their properties are the three main goals of the Department of Chemical Biology (CBIO) at the HZI.
Biostatistics
High-Throughput-technologies generate large amounts of data. The drawback: these biological and medical data must be processed to results with statistical methods and models. Concepts from robust and computational statistics as well as visualisation techniques help to better understand, estimate and cope with the uncertainty and strong variation that are often inherent in biological and medical data. The project group „Biostatistics“ is part of the research group „Cellular Proteome Research” which is led by Lothar Jänsch.
Biomarkers of Infectious Diseases
The Research Group Biomarkers of Infectious Diseases aims to identify more accurate diagnostic, prognostic and predictive host biomarkers for infectious diseases and the vaccine response. The clinical aims of the group are to help select the most effective, individualized treatment as early as possible, aiming to streamline the use of anti-infectives (improve anti-infective stewardship) and to improve clinical outcome. This group is located at the TWINCORE in Hannover.
Biological Barriers and Drug Delivery
While considering the confusing flood of drugs in the pharmacies it is hard to believe in a lack of medication. But there are still many infectious diseases and also cancer that cannot be treated sufficiently. During a medical treatment it is essential that the drug arrives at the envisaged body region. Read more about the research of the department “Biological Barriers and Drug Delivery” on techniques for the correct distribution of novel drugs. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .
Antiviral and Antivirulence Drugs
Work in the Empting lab focuses on tackling innovative and difficult-to-address anti-infective targets such as bacterial virulence regulatory systems as well as un(der)explored anti-herpesviral persitance mediators. By this, we aspire to circumvent common resistance mechanisms and to refill the dried out development pipeline. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
Compound Profiling and Screening
The World Health Organization (WHO) considers the spread of microorganisms which are resistant to the most common antibiotics an increasing threat to the well-being of the world population. Not only is the number of patients increasing whose infectious disease can no longer be treated, but also in some circumstances patients with other severe diseases will not be treated if the therapy is accompanied with suppression of the immune system and thus, an increased risk of infection. Thus, new active agents for the treatment of infectious diseases are urgently needed, as well as the responsible use of existing antibiotics. Prerequisites for the discovery of new drugs are relevant biological screening assays together with compound libraries of broad chemical diversity. We perform primary screens, based either on own protocols or on protocols developed by cooperation partners and transferred to our infrastructure. In cooperation with partners we also perform secondary assays to optimize first primary hits.
Computational Biology for Individualised Medicine
Infections are among the biggest threats to health and the most significant causes of death worldwide. Our aim is to reveal the host genetic risk factors and their downstream molecular pathways, which are crucial to make progress in understanding and treating infectious diseases in an individualised manner as well as to improve the identification of patients at risk. The department is part of the developing CiiM and currently housed at the TWINCORE in Hannover.
Experimental Immunology
Immune cell populations are characterized by a high degree of heterogeneity to enable efficient and specialized responses to the diverse set of pathogens. This is particularly true for cells of the adaptive immune system, but also innate immune cell populations are heterogeneous and can adapt to different environmental conditions. Adaptation of immune cells is often associated with epigenetic alterations that lead to the fixation of gene expression patterns, finally resulting in cells with highly specialized fates, phenotypes and functional properties.
Evolutionary Community Ecology
Humans are increasingly part of these interaction networks and pathogen transmission from animals to humans is occurring at increasing rates. Indeed, emerging zoonotic disease are an increasing threat to human health and most of these diseases have their origins in wildlife. Microorganisms and their associated diseases also influence animal populations’ persistence and conservation, with some spilling over to animals from humans as well. The research group ‘evolutionary community ecology’ explores how the changing composition of animal communities has cascading impacts on their microbial communities, diseases, and rates of transmission, including to humans. The department is located at the Helmholtz Institute for One Health .
